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Abstract. Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer’s disease biomarkers in many
clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic
value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on
to have amyloid PET. The treating neurologist’s working diagnosis, and degree of diagnostic certainty, was assessed both
before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic
value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.
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INTRODUCTION
Differentiating the underlying pathological causes
of dementia is important but often challenging.
Amyloid PET can identify fibrillar amyloid- (A)
deposition, a core aspect of Alzheimer’s disease (AD)
pathology, in vivo [1]. However, cost, availability, and
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paucity of evidence that it changes management are
factors that limit its clinical use. Proposed “appropri-
ateuse”criteria suggest that amyloidPETmaybeused
in unexplained mild cognitive impairment, young-
onset dementia, and atypical dementia syndromes [2,
3]. CSF measures of amyloid and tau provide an alter-
nate means of substantiating a molecular diagnosis of
AD [4], with broadly similar diagnostic performance
to amyloid PET when either is used in isolation [5]. In
many clinical centers, CSF measures remain the first
line AD molecular biomarker.
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While previous studies assessing the use of amy-
loid PET in the clinical setting have found it to provide
added diagnostic value, patients included in these
studies have often had incomplete prior investigative
work-up, in some cases without MRI, neuropsychom-
etry, and/or CSF [6–9]. Few studies have assessed
the utility of amyloid PET in circumstances where it
may prove most useful, i.e., in cases fulfilling good
use criteria in whom a CSF has been performed and
an equivocal/uncertain result is obtained and there
remains clinical equipoise as to whether the patient
has AD pathology or not. In this study, we aimed to
determine in a real life clinical setting whether amy-
loid PET can provide added diagnostic value beyond
CSF measurements alone; and in what specific clin-
ical circumstances the addition of amyloid PET is
likely to provide the most benefit.
MATERIALS AND METHODS
Twenty patients with a range of different dementia
syndromes were recruited from a Specialist Cog-
nitive Disorders Service (Supplementary Table 1).
Ten had memory-led syndromes; the remainder had
a range of other presentations including posterior
cortical atrophy (n = 5), primary progressive apha-
sia (PPA) (n = 4), and behavioral change (with the
patient becoming impulsive and socially disinhibited)
(n = 1). As part of their routine clinical evalua-
tion, each patient had been seen by an experienced
cognitive neurologist, and been investigated with
neuropsychological testing, MR brain imaging and
lumbar puncture, with samples analyzed for A42,
total tau, and p-tau (INNOTEST ELISAs, Fujirebio,
Ghent Belgium). At the time of testing, the normal
clinical ranges for CSF measures in use were: A42
>450 ng/L, tau:A42 ratio <1, p-tau <68 ng/L. Tau
and A42 cut-points were those in use clinically at
our center at the time of the study, and were based
on reference ranges of healthy controls and ability
to distinguish clinically diagnosed AD from FTD;
the p-tau cut-point was that determined by the kit
manufacturer.
As part of a research study, each patient subse-
quently had an F18 florbetapir PET scan on a Siemens
3T PET/MR unit, with a 50-min dynamic acquisition
commencing immediately after intravenous injection
of 370 MBq of florbetapir. A volumetric T1-weighted
MRI scan was acquired concurrently. A single static
PET image, reconstructed from the last 10 min of the
PET acquisition, was used for analysis. Three nuclear
medicine physicians, blinded to the diagnosis, visu-
ally rated the images as positive/negative according
to standard criteria.
With the benefit of the psychology, MRI, and CSF
results, but prior to the PET scan, the treating clin-
ician was asked to give their diagnosis and degree
of diagnostic certainty (on a percentage scale). The
clinician was subsequently provided with the PET
scan result, which with their consent was also shared
with the patient, and asked again to give the diagno-
sis/diagnostic certainty. The study received ethical
approval and all patients gave written informed
consent.
RESULTS
The patients had a mean ± SD age of 65.5 ± 7.6,
and age of symptom onset of 59.2 ± 6.2. CSF exam-
ination preceded scanning, with a median delay of
145 days (range 32–427). Across all subjects, CSF
A42 ranged between 343–1127 ng/L, tau/A42 ratio
0.24–2.54, and p-tau 24–227 ng/L.
Prior to the amyloid PET, 13 patients had a diagno-
sis of AD, and seven of non-AD dementia. Pre-PET
diagnostic certainty was 68 ± 16%. Based on the
visual PET results, 18 patients were amyloid positive
and 2 patients amyloid negative, with no disagree-
ment between the three readers for any scan. The
amyloid PET result led to a change in diagnosis in
7/20 patients (5 non-amnestic, 2 amnestic) (Table 1).
Six patients’ diagnoses changed from non-AD to AD;
and 1 from AD to non-AD. The PET scan result led to
an increase in diagnostic certainty in 18/20 patients
(to a mean 84 ± 14%). Management was changed
in 8/20 patients: an acetylcholinesterase inhibitor
was started/stopped (n = 4); memantine was started
(n = 1); immune suppression was stopped (n = 1); and
AD genetic testing was requested (n = 2).
Of the seven individuals in whom the PET led to
a change in diagnosis, all had young-onset demen-
tia (age-at-onset <65 y), and five had non-amnestic
syndromes, particularly primary progressive aphasia
(n = 4) (Table 1, Supplementary Table 1). Clinically,
the PPA cases had each been felt to be most con-
sistent with progressive non-fluent aphasia (PNFA),
although three of the four cases did not fulfill one of
the canonical PPA syndromes, having some features
additionally consistent with a logopenic aphasia (e.g.,
anomia and word finding pauses). The seven cases
in whom the PET scan altered the diagnosis had a
rather lower pre-PET diagnostic certainty than the
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Table 1
Details of the patients in whom there was a change in diagnosis following the PET scan: Clinical information, including presenting symptom,
CSF results, PET result, and details of change in diagnosis and diagnostic certainty (comparing before PET and after PET). The normal
ranges for CSF measures used at our center were: A1-42 >450 ng/L, tau:A1-42 ratio <1, p-tau <68 ng/L
Patient ID Presenting symptom CSF measures Florbetapir PET result Change in diagnosis Diagnostic certainty
A1-42 tau:A p-tau
1 Speech difficulty 513 1.06 61 Positive FTD to AD 40% → 60%
4 Speech difficulty 544 0.56 39 Positive FTD to AD 60% → 80%
5 Episodic memory 630 0.24 24 Negative AD to depression 50% → 90%
6 Speech difficulty 403 0.58 26 Positive FTD to AD 80% → 60%
10 Behavioral change 729 0.54 49 Positive FTD to AD 40% → 60%
16 Episodic memory 393 0.94 50 Positive Autoimmune to AD 50% → 60%
20 Speech difficulty 601 0.88 57 Positive FTD to AD 65% → 95%
rest of the group (55% versus 76%). Also, the CSF
results for these cases were generally close to the pre-
determined CSF diagnostic cut-points, particularly
for the tau:A42 ratio (Table 1, Fig. 1).
DISCUSSION
Providing molecular evidence to support/refute a
diagnosis of AD will become ever more important as
we move toward an era of disease-modifying thera-
pies. In many centers, CSF measurements remain the
first-line molecular biomarker of choice. Here, we
show that in certain situations, amyloid PET provides
added diagnostic value above and beyond CSF mea-
surements, leading not only to increased diagnostic
certainty but also to changes in management.
We found that amyloid PET had most benefit in
two particular scenarios, (1) in patients with young
onset, atypical clinical syndromes; and (2) in those
where there was diagnostic uncertainty despite oth-
erwise comprehensive investigation. These findings
are consistent with “appropriate use” criteria [2], but
also extend on the previous guidelines by assessing
the use of amyloid PET in patients who have already
had CSF amyloid and tau measurements; which in
most clinical centers is likely to be the situation where
amyloid PET may most commonly be used.
Atypical (i.e., non-amnestic) syndromes may be
underpinned by a variety of different underlying
pathologies and this is particularly the case for
PPA, where a tauopathy, TDP-43 proteinopathy, and
AD are all possibilities. Although consensus clinical
diagnostic criteria describe three major forms (PNFA,
logopenic aphasia, and semantic dementia), in many
cases patients do not easily fulfill any one criteria
[10, 11]. Additionally, while there is good clinico-
pathological correspondence in some of the PPA
syndromes, notably semantic dementia and logopenic
aphasia (TDP43 and AD, respectively), in no
syndrome is this perfect; and in non-fluent apha-
sia and undetermined aphasias ascribing a particular
pathology is notoriously difficult [12, 13].
While previous studies have found relatively high
concordance between CSF measures and amyloid
PET [14, 15], atypical AD syndromes may have less
clear-cut CSF profiles than would normally be seen
in typical AD [16]. This subtle variability between
the CSF profiles of different AD syndromes, com-
bined with the high proportion of atypical cases in
our cohort, may have contributed in some cases to
diagnostic uncertainty and the discrepancy between
the CSF and PET results. Cases where there was most
diagnostic uncertainty were often those where the
CSF levels were equivocal, lying close to or even
outside diagnostic cut-points. No CSF cut-point is
perfect, and it is possible that the CSF cut-points in
clinical use at the time of this study were overly con-
servative. CSF values can vary substantially if not
taken, handled, and stored appropriately; and estab-
lishing CSF cut-points is difficult, as evidenced by
the wide differences in normal ranges used at different
clinical centers [17], leading us and others to propose
the adoption of diagnostic grey-zones, and to suggest
that comparing CSF and amyloid PET results may be
useful in refining CSF cut-point use [18]. This study
reinforces that it is just such equivocal cases—with
atypical phenotypes and borderline CSF results—that
addition of an amyloid brain scan may be most useful,
and that so doing can alter clinical management.
Given the known incidence of cerebral amyloid
deposition within the asymptomatic aging popula-
tion [19], it is always necessary to consider whether a
positive amyloid PET scan reflects the primary cause
of a patient’s symptoms, or if it is merely reflective
of a second coincident pathology. This possibility
was considered by the treating clinician in each case.
However, particularly considering the patients’ rela-
tively young ages of symptom onset, the possibility
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Fig. 1. A comparison of CSF values for those with positive and negative amyloid PET scans: Scatter plots show CSF results for (A) A42,
(B) total tau, (C) tau:A42, and (D) p-tau for PET positive and negative cases. For two individuals, p-tau measurement had not been possible.
Those individuals in whom the amyloid PET scan led to a change in diagnosis are indicated by an X next to the corresponding CSF value.
of dual pathology was felt to be unlikely, again in
keeping with the inclusion of young-onset dementia
as an “appropriate use” criterion for amyloid PET.
Our study has a number of limitations. There were
in some cases significant delays between the CSF
and PET scan. However, as A load is thought to
plateau prior to the onset of AD symptoms, this delay
is unlikely to have had a significant effect on the
relative diagnostic utility of the two tests [20], and
also reflects what is likely to happen in real life clini-
cal practice. And, without pathological confirmation,
we cannot know whether any diagnostic or man-
agement changes following the amyloid PET were
correct or not.
This study demonstrates that amyloid PET scan-
ning has clinical utility is some cases in addition
to CSF examination, and provides evidence to sup-
port its use particularly in young-onset, atypical
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dementias, where CSF results are borderline and
diagnostic uncertainty remains.
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